Asit Parikh Biography and Net Worth

Dr. Parikh, M.D., Ph.D., is the President and Chief Executive Officer of MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease.

Previously, Dr. Parikh served as senior vice president and head of the Gastrointestinal Therapeutic Area at Takeda Pharmaceuticals.

Dr. Parikh earned his Ph.D. in biochemistry and his M.D. from Vanderbilt University, and was a resident in internal medicine at the University of Pennsylvania. He then completed subspecialty training in gastroenterology at the Massachusetts General Hospital, with postdoctoral work in cancer biology at Massachusetts Institute of Technology. He also remains actively engaged in the practice of gastroenterology and internal medicine as a part-time coverage staff physician at Newton-Wellesley Hospital.

What is Asit Parikh's net worth?: The estimated net worth of Asit Parikh is at least $1.33 million as of May 6th, 2025. Parikh owns 90,500 shares of Phathom Pharmaceuticals stock worth more than $1,330,350 as of December 5th. This net worth approximation does not reflect any other investments that Parikh may own. Learn More about Asit Parikh's net worth.
How do I contact Asit Parikh?: The corporate mailing address for Parikh and other Phathom Pharmaceuticals executives is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. Phathom Pharmaceuticals can also be reached via phone at 877-742-8466 and via email at [email protected]. Learn More on Asit Parikh's contact information.
Has Asit Parikh been buying or selling shares of Phathom Pharmaceuticals?: Asit Parikh has not been actively trading shares of Phathom Pharmaceuticals during the past quarter. Most recently, on Tuesday, May 6th, Asit Parikh bought 5,000 shares of Phathom Pharmaceuticals stock. The stock was acquired at an average cost of $2.60 per share, with a total value of $13,000.00. Following the completion of the transaction, the director now directly owns 90,500 shares of the company's stock, valued at $235,300. Learn More on Asit Parikh's trading history.
Who are Phathom Pharmaceuticals' active insiders?: Phathom Pharmaceuticals' insider roster includes Terrie Curran (Insider), Molly Henderson (CFO), Frank Karbe (Director), Azmi Nabulsi (COO), Asit Parikh (Director), David Socks (Director), and James Topper (Director). Learn More on Phathom Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Phathom Pharmaceuticals?: During the last year, Phathom Pharmaceuticals insiders bought shares 3 times. They purchased a total of 21,280 shares worth more than $126,715.80. During the last year, insiders at the sold shares 9 times. They sold a total of 42,342 shares worth more than $284,083.77. The most recent insider tranaction occured on November, 3rd when insider Robert Charles Breedlove sold 524 shares worth more than $7,079.24. Insiders at Phathom Pharmaceuticals own 23.0% of the company. Learn More about insider trades at Phathom Pharmaceuticals.
Information on this page was last updated on 11/3/2025.

Asit Parikh Insider Trading History at Phathom Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/6/2025	Buy	5,000	$2.60	$13,000.00	90,500
11/8/2023	Buy	2,500	$7.80	$19,500.00	55,000
11/6/2023	Buy	1,000	$8.04	$8,040.00	48,500
4/10/2023	Buy	1,000	$7.55	$7,550.00	23,500
2/13/2023	Buy	5,000	$7.73	$38,650.00	22,500
1/12/2023	Buy	5,000	$7.00	$35,000.00	17,500
5/12/2022	Buy	12,500	$8.00	$100,000.00	12,500

Asit Parikh Buying and Selling Activity at Phathom Pharmaceuticals

Phathom Pharmaceuticals Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Today's Range

Now: $14.70

$14.27

$14.91

50 Day Range

MA: $13.53

$10.84

$15.60

2 Week Range

Now: $14.70

$2.21

$16.26

Volume

529,916 shs

Average Volume

812,243 shs

Market Capitalization

$1.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43